Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles W Flexner

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
The Hopkins HIV Report : a Bimonthly Newsletter for Healthcare Providers|December 23, 2003
Pharmacology in ParisCharles W Flexner
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|April 30, 2003
Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoringCharles W Flexner
Current Opinion in HIV and AIDS|December 6, 2021
Editorial: New drugs for HIV: quo vadis?Charles W Flexner, Angela Kashuba
AIDS (London, England)|May 31, 2002
Concentration-targeted therapy and the future of HIV managementCharles W Flexner, Stephen C Piscitelli
Current Opinion in HIV and AIDS|April 4, 2017
Universal antiretroviral regimens: thinking beyond one-pill-once-a-dayJeffrey M Jacobson, Charles W Flexner
Current Opinion in HIV and AIDS|April 14, 2017
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settingsGary Maartens, Marta Boffito, Charles W Flexner
Journal of Clinical Pharmacology|January 21, 2017
Medication AdherenceDavid Lawrence, James H Miller, Charles W Flexner
Current Opinion in HIV and AIDS|May 10, 2017
Why a universal antiretroviral regimen?Charles W Flexner, Polly Clayden, Willem D F Venter
AIDS Patient Care and Stds|January 7, 2003
Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden?Gregory M Lucas, Charles W Flexner, Richard D Moore
Journal of Acquired Immune Deficiency Syndromes (1999)|July 2, 2005
The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosingDavid J Back, David M Burger, Charles W Flexner, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Hopkins HIV Report : a Bimonthly Newsletter for Healthcare Providers|December 23, 2003
Pharmacology in ParisCharles W Flexner
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|April 30, 2003
Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoringCharles W Flexner
Current Opinion in HIV and AIDS|December 6, 2021
Editorial: New drugs for HIV: quo vadis?Charles W Flexner, Angela Kashuba
AIDS (London, England)|May 31, 2002
Concentration-targeted therapy and the future of HIV managementCharles W Flexner, Stephen C Piscitelli
Current Opinion in HIV and AIDS|April 4, 2017
Universal antiretroviral regimens: thinking beyond one-pill-once-a-dayJeffrey M Jacobson, Charles W Flexner
Current Opinion in HIV and AIDS|April 14, 2017
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settingsGary Maartens, Marta Boffito, Charles W Flexner
Journal of Clinical Pharmacology|January 21, 2017
Medication AdherenceDavid Lawrence, James H Miller, Charles W Flexner
Current Opinion in HIV and AIDS|May 10, 2017
Why a universal antiretroviral regimen?Charles W Flexner, Polly Clayden, Willem D F Venter
AIDS Patient Care and Stds|January 7, 2003
Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden?Gregory M Lucas, Charles W Flexner, Richard D Moore
Journal of Acquired Immune Deficiency Syndromes (1999)|July 2, 2005
The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosingDavid J Back, David M Burger, Charles W Flexner, et al.
Pageof 2